Yiyi Shenzhou completed a new round of financing to further expand the gene cell drug pipeline.

On October 16, 2020, Yimyo Shenzhou announced that the company had completed a new round of financing, with the investor being Zhongguancun Longmen Fund.
fund raising will be used primarily to support the company's new cancer product pipeline development and accelerate the process of product launch.
, Founded in 2015, Beijing Yiyi Shenzhou Pharmaceutical Technology Co., Ltd. is a new biopharmaceutical company dedicated to the application of innovative gene cell drug technology to the treatment of malignant tumors.
the core technology of Yiyi Meizhou are independent research and development, the company has a one-stop gene cell drug platform, master the core technology of research and development and production.
Yimyo shenzhou independently developed a car-T cell therapy candidate product targeting CD19 antigens- IM19 inlay antigen-inset antigen-liked T-cell injection, has been in April this year to obtain two clinical trial notifications, and in July completed the first trial participants into the group.
addition to IM19, the company has laid out a number of CAR-T cell product pipelines for hematomas and solid tumors, some of which are in the IND preparation phase and are expected to submit IND applications next year.
company's mission is to "make cancer no longer terminal" and to "be a world-class gene cell drug company".
has won the national high-tech enterprises, Beijing "major new drug creation special", Beijing "science and technology new star", Beijing science and technology-based enterprise innovation funds, Beijing "eagle talent", Zhongguancun frontier reserve project, China's most investment value enterprises 50, Tsinghua University x-lab annual innovation star and other qualifications and honors.
"Over the past few years, China's gene cell drug industry has developed rapidly and accumulated a number of outstanding innovations," said Dr. He Wei, founder and CEO of Beijing Yiyi Shenzhou Pharmaceutical Technology Co., Ltd.
, the industry will enter a new stage of development, we will jointly welcome China's first CAR-T cell drugs to market and commercialization.
this time to win the favor of Longmen investment, but also strengthen our continued development of "differentiation and industrialization" research and development matrix confidence.
will continue to make its own contribution to the cause of cancer treatment, as always, by adhering to independent research and development and innovation.
, chairman of Zhongguancun Longmen Investment, said, "He Wei is one of the elite members of the Yajie Chamber of Commerce."
's mission is to support and empower entrepreneurs who are struggling for China's scientific and technological innovation.
in the field of biomedical immunotherapy, we have been focusing on truly innovative companies.
is honored to participate in the development of Yiyi Shenzhou.
is a young team, but with its rigorous research and development path, rooted in the spirit of clinical exploration, as well as its excellent innovation ability, has established its own technology "moon."
The CAR-T platform independently developed by Yimyo Shenzhou has reached the international advanced level and is also the new force of precision medicine in China, and we look forward to Yiyi Shenzhou continuing to lead Chinese innovative enterprises to continue to deeply cultivate scientific research, seek breakthroughs and expand the possibilities of cancer immunotherapy.
" Art Magic Shenzhou Source: Yimei Shenzhou Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mays Medical, and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.